Pasireotide in Hyperinsulinemic Hypoglycemia

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 30, 2017

Primary Completion Date

January 31, 2018

Study Completion Date

April 30, 2018

Conditions
Congenital HyperinsulinismInsulinomaHyperinsulinism
Interventions
DRUG

Pasireotide 0.6Mg Solution for Injection

Pasireotide 0.6Mg Solution for Injection will be given once per study visit

DRUG

Saline Solution

Saline Solution injection will be given once per study visit

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Montefiore Medical Center

OTHER